Updated:
Jeisys Medical
DH Kang's Jeisys Medical has installed over 15,000 energy-based aesthetic systems globally and is now expanding directly into the U.S. market.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
Asia
Country
South Korea
City
Seoul
Corporate office
Seoul, South Korea
Additional offices
Burlington, MA, United States
Principals
DH Kang
Founder
Sector focus
Frequently asked questions
Who runs investment decisions at Jeisys Medical?
Jeisys is an operating medical device manufacturer, not an investment firm. Strategic and financial decisions are guided by founder DH Kang alongside majority investor Archimed, an $8B healthcare private equity firm that acquired its stake in 2023.
Is Jeisys Medical structured as a family office or an asset manager?
Neither. Jeisys is a vertically integrated manufacturer of aesthetic medical devices. It designs, produces, and sells its own RF and resurfacing platforms. The firm's North American unit, Jeisys Medical North America, functions as a direct sales and training subsidiary.
How is Jeisys Medical related to Archimed?
Archimed, a global private equity firm dedicated to healthcare, acquired a majority stake in Jeisys Medical in September 2023 (per the Jeisys website, 2025). The investment is designed to finance Jeisys's direct entry into the U.S. aesthetics market.
What is Jeisys Medical's known posture on co-investments alongside external GPs?
Jeisys does not co-invest in a traditional sense. It has accepted growth capital from Archimed, a healthcare-specialized investment firm. There is no evidence that it participates in GP relationships beyond this controlling stake.
Which sectors does Jeisys Medical explicitly avoid?
Jeisys focuses exclusively on energy-based aesthetic devices, specifically RF microneedling, dual-mode RF, and fractional resurfacing platforms. The firm does not operate in surgical aesthetics, injectables, or non-device skincare products.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: